U.S. Age-Related Macular Degeneration Market Hits US$5.0 Bn in 2025, Anti-VEGF Leads Revenue - Outlook to 2033 | DataM Intelligence

Leander, Texas and TOKYO, Japan - Nov. 21. 2025

The United States Age-Related Macular Degeneration (AMD) market reached US$ 5.00 billion in 2024 and is expected to reach approximately US$ 9.20 billion by 2034, growing at a CAGR of 6.8% during the forecast period 2025-2034

The Global Age-Related Macular Degeneration Market reached US$15.43 billion in 2024 and is expected to reach US$26.58 billion by 2033, growing at a CAGR of 6.3% during the forecast period 2025-2033, according to DataM Intelligence report.

Download your exclusive sample report today: (corporate email gets priority access):https://www.datamintelligence.com/download-sample/age-related-macular-degeneration-market?praveen

Recent Industry Developments - U.S. AMD Market

🔹 October 2025 - Long-acting anti-VEGF pipeline accelerates commercialization
Leading biopharma companies are racing to introduce extended-duration AMD therapies that reduce treatment frequency, improve patient adherence, and sustain retinal function. This supports precision-medicine adoption, helping clinicians better manage wet AMD progression and vision preservation.

🔹 September 2025 - Surge in AI-enabled retinal imaging and early screening integration
U.S. hospitals and ophthalmology networks are adopting real-time OCT imaging with predictive AI models for early AMD detection. The shift is reducing late-stage treatment costs and improving visual outcomes by engineering proactive care workflows.

🔹 June 2025 - Gene therapy approvals reshape treatment landscape
Regenerative medicine investments are accelerating as gene-based pipelines gain U.S. FDA fast-track and breakthrough therapy designations. These technologies aim to restore photoreceptor functions, offering more durable functional vision improvement for late-stage AMD patients.

Recent Industry Developments - Japan AMD Market

🔹 August 2025 - Advanced biologics driving wet AMD therapy upgrades
Japan sees rising clinical adoption of next-gen anti-VEGF biologics supported by strong real-world data demonstrating superior fluid control and extended treatment intervals. This trend is reducing injection burden and improving patient quality of life.

🔹 June 2025 - AI-enabled retinal imaging grows across national eye-care systems
Japanese clinics are integrating automated OCT image analysis and predictive disease-risk algorithms to identify early AMD onset enhancing screening and reducing late-stage vision loss care costs. This digital transformation aligns with Japan's smart healthcare adoption strategies.

🔹 April 2025 - Regenerative cell-based therapies gain momentum in R&D pipeline
Japan's strong leadership in iPSC (induced pluripotent stem cell) innovation is fueling new sight-restoration technologies targeting dry and late-stage AMD. Investments from major ophthalmology innovators are accelerating therapy translation from clinical trials to commercial readiness.

(AMD) Market: Key Drivers

The Age-Related Macular Degeneration (AMD) market is expanding rapidly as the global aging population rises and the prevalence of retinal diseases increases. With AMD being a leading cause of vision loss in individuals aged 60 and above, healthcare systems are prioritizing early diagnosis and effective treatment options to prevent irreversible blindness.

Advancements in anti-VEGF biologics, sustained-release implants, and AI-enabled retinal imaging are significantly improving treatment outcomes. The increasing adoption of personalized and minimally-invasive therapies, supported by strong R&D investments, is accelerating the shift toward next-generation AMD care.

Lifestyle-related risk factors such as smoking, hypertension, and higher screen exposure are further contributing to AMD incidence. Expanding healthcare access, government-funded awareness programs, and a strong pipeline of gene and cell therapies are helping the market maintain its momentum as demand grows for vision-preserving treatment solutions.

Get Customization in the report as per your requirements:https://www.datamintelligence.com/customize/age-related-macular-degeneration-market?praveen

(AMD) Market: Major Players

1. Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc. remains one of the most dominant companies in the Age-Related Macular Degeneration (AMD) Market, driven by its blockbuster eye therapy Eylea and the high-dose formulation Eylea HD. Regeneron publicly reports performance in the AMD and diabetic eye disease segment, and recent earnings show that Eylea and Eylea HD together captured approximately 46% share in the relevant retinal-disease market segment including AMD, reinforcing the company's leadership position.

2. Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc. is strengthening its presence in the fast-growing geographic atrophy (GA) subtype of AMD. Its therapy Syfovre has rapidly gained commercial traction, with the company reporting more than 60% total market share in GA treatment and over 52% of new patient initiations in the latest quarter. This positions Apellis as a key growth driver in the dry AMD treatment landscape.

3. Astellas Pharma Inc.
Astellas Pharma Inc. is recognized as a major participant in the AMD therapeutics market, supported by multiple market analyses listing the company among leading contributors to AMD-focused innovation and portfolio expansion. However, publicly disclosed information does not provide a specific AMD market-share figure for Astellas at this time.

Segment Covered in the (AMD) Market:

A ) By Treatment
The AMD market is segmented based on the type of therapeutic approach adopted to manage disease progression and improve visual outcomes:

1. Anti-VEGF Drugs
These biologic therapies dominate the treatment landscape, especially for wet AMD, by blocking vascular endothelial growth factor (VEGF) to prevent abnormal blood vessel growth and fluid leakage in the retina. Leading products include Eylea, Lucentis, Beovu, and emerging biosimilars. High clinical efficacy and ongoing advancements in long-acting and combination therapies make this the largest revenue-generating segment.

2. AREDS2 Supplements
Nutritional formulations recommended mainly for intermediate and late-stage dry AMD. They contain antioxidants, zinc, lutein, and zeaxanthin to slow macular degeneration progression. Growing awareness of early intervention, preventive eye-care habits, and consumer self-medication trends supports steady growth in this segment.

3. Photodynamic Therapy (PDT)
This treatment combines a photosensitizing drug (such as verteporfin) with a low-intensity laser to seal leaking blood vessels. While its usage has declined with the widespread adoption of Anti-VEGF drugs, PDT remains relevant for specific AMD subtypes and patients unresponsive to injections.

B ) By Patient Type
AMD prevalence differs based on demographic and genetic factors, influencing treatment demand:

1.Male Patients
Men exhibit a slightly higher risk of developing late-stage AMD, particularly with lifestyle-associated risk factors such as smoking and cardiovascular conditions. This group accounts for a significant share of treatment uptake, especially for advanced wet AMD therapies.

2.Female Patients
Women represent a major patient pool because they tend to live longer, increasing the likelihood of age-related retinal deterioration. Higher awareness of preventive eye-care and health management also supports greater demand for AREDS2 supplements and frequent screening services among female patients.

Regional Analysis

1) North America
-North America holds around 48% of the global Age-Related Macular Degeneration (AMD) Market, making it the largest regional contributor, driven by strong adoption of Anti-VEGF biologics, high diagnosis rates, and favorable reimbursement structures in the U.S. and Canada.

2) Europe
- Europe accounts for about 23% of the AMD market, supported by universal healthcare systems, structured ophthalmology guidelines, and a large elderly population across Germany, the U.K., France, Italy, and Spain.

3) Asia-Pacific
- Asia-Pacific represents nearly 19% of global AMD revenues but is considered the fastest-growing region, with Japan, China, South Korea, and Australia driving demand due to rapid population aging and improved access to retinal imaging and intravitreal therapies.

4) Latin America
- Latin America captures around 5% of the AMD market, with Brazil, Mexico, and Argentina leading growth as ophthalmology infrastructure develops and awareness of retinal diseases gradually increases.

5) Middle East & Africa
- Middle East & Africa together account for approximately 5% of market share, reflecting an early-stage but expanding AMD treatment landscape as healthcare systems modernize and the burden of diabetes and hypertension raises demand for retinal care.

Purchase this report before year-end and unlock an exclusive 30% discount:
https://www.datamintelligence.com/buy-now-page?report=age-related-macular-degeneration-market?praveen
(Purchase 2 or more Repots and get 50% Discount)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?praveen

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.